FOXM1 and cancer: Consistent with the observation that FoxM1 silencing is connected to reduced tumorigenicity (79), we found Artemisinin to considerably mitigate growth and clonogenicity of Hep3BshFoxM1 cells, implying the potential of this natural product in delaying or preventing tumor relapse in cancer patients (Figures 3F, G).